January 29-31 2019
Boston, MA

 

 

Day One
Wednesday January 30th, 2019

Day Two
Thursday January 31st, 2019

08.30
Coffee & Registration

09.15
Chairman’s Opening Remarks

New Developments in PARP Inhibitors & Novel DDR Pathway Targets

09.30
Discovery & Clinical Development of IMP4297, A Potential Best-in-Class PARP Inhibitor

10.00
Preclinical Characterization of a Clinical Development Candidate CC-115, a Dual Inhibitor of mTOR Kinase and DNA-PK

  • Shuichan Xu Senior Principal Scientist & Group Leader, Celgene

10.30
Morning Refreshments & Speed Networking

11.30
Panel Discussion: Assessing Lessons Learnt from Clinical Success and Challenges of PARP Inhibitors

  • Geoffrey Shapiro Director, Early Drug Development Center , Dana Farber Cancer Institute
  • J. Carl Barrett Vice President of Translational Science in Oncology, AstraZeneca
  • Graeme Smith Chief Scientific Officer, Artios Pharma Ltd.

12.30
Targeting Spliceosome Mutations in Cancer Cells to Advance Therapeutics ATR Inhibitors

  • Lee Zou Professor Pathology , Harvard Medical School

13.00
Lunch & Networking

14.00
AsiDNA, A First-in-Class Decoy Oligonucleotide Targeting DNA Repair to Kill Tumor Cells

14.30
PARP Inhibitors in the New Era, New Targets & New Targeting Techniques

15.00
Scientific Poster Session & Networking

15.30
Roundtable Discussions

16.30
Chair’s Closing Remarks

16.45
End of Day One